Abstract:Autologous transplantation and engraftment of HIV-resistant cells in sufficient numbers should recapitulate the functional cure of the Berlin Patient, with applicability to a greater number of infected individuals and with a superior safety profile. A robust preclinical model of suppressed HIV infection is critical in order to test such gene therapy-based cure strategies, both alone and in combination with other cure strategies. Here, we present a nonhuman primate (NHP) model of latent infection using simian/human immunodeficiency virus (SHIV) and combination antiretroviral therapy (cART) in pigtail macaques. We demonstrate that transplantation of CCR5 gene-edited hematopoietic stem/progenitor cells (HSPCs) persist in infected and suppressed animals, and that protected cells expand through virus-dependent positive selection. CCR5 gene-edited cells are readily detectable in tissues, namely those closely associated with viral reservoirs such as lymph nodes and gastrointestinal tract. Following autologous transplantation, tissue-associated SHIV DNA and RNA levels in suppressed animals are significantly reduced (p ≤ 0.05), relative to suppressed, untransplanted control animals. In contrast, the size of the peripheral reservoir, measured by QVOA, is variably impacted by transplantation. Our studies demonstrate that CCR5 gene editing is equally feasible in infected and uninfected animals, that edited cells persist, traffic to, and engraft in tissue reservoirs, and that this approach significantly reduces secondary lymphoid tissue viral reservoir size. Our robust NHP model of HIV gene therapy and viral persistence can be immediately applied to the investigation of combinatorial approaches that incorporate anti-HIV gene therapy, immune modulators, therapeutic vaccination, and latency reversing agents.

Cell membrane anchoring strategies for HIV gene therapy

Research progress on HIV latency-reversing agents and its mechanism

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Strategies for HIV-1 suppression through key genes and cell therapy

Gene therapy for HIV infection

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Advanced Therapies for Human Immunodeficiency Virus

Advancements in Cell-Based Therapies for HIV Cure

Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure

HIV Pol: does it offer therapeutic targets for HIV?

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

HIV-1 functional cure: will the dream come true?

Altering cell death pathways as an approach to cure HIV infection

Advancements in Developing Strategies for Sterilizing and Functional HIV Cures

Targeting CCR5 for anti-HIV research

Strategies for Inhibiting Function of HIV-1 Accessory Proteins: A Necessary Route to AIDS Therapy?

CXCR4 Is a Potential Target for Anti-HIV Gene Therapy

Targeting HIV persistence in the tissue

Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy.

Strategies for human immunodeficiency virus cure：current status and future prospects